Parmax Pharma Limited has received in-principle approval from BSE Limited for its proposed preferential issue of securities. The approval was granted vide letter no. LOD/PREF/DA/FIP/693/2026-27 dated August 21, 2026, under Regulation 28(1) of the SEBI LODR Regulations.
The approval covers the issuance of:
- 31,37,586 (Thirty One Lakh Thirty Seven Thousand Five Hundred and Eighty Six) Equity Shares of face value ₹10 each
- 21,45,145 (Twenty One Lakh Forty Five Thousand One Hundred and Forty Five) Warrants convertible into an equal number of Equity Shares of face value ₹10 each
Both equity shares and warrants will be issued at a price of not less than ₹36.50 per security. The issuance is to be made to allottees as per the Notice of the EGM referenced in the company's previous intimation dated June 8, 2026.
The in-principle approval is subject to necessary compliance under applicable SEBI regulations. The company has requested BSE to take this information on record.
The disclosure is signed by Umang Gosalia (DIN: 05153830), Managing Director of Parmax Pharma Limited.
Financial Impact
Potential equity dilution through issuance of 31,37,586 equity shares and 21,45,145 convertible warrants. Total fund raising potential of approximately ₹19.30 crore based on minimum issue price of ₹36.50 per security.